Search Results for "bevacizumab"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for bevacizumab. Results 21 to 21 of 21 total matches.
See also: Avastin

Faricimab (Vabysmo) for Age-Related Macular Degeneration and Diabetic Macular Edema

   
The Medical Letter on Drugs and Therapeutics • Mar 21, 2022  (Issue 1646)
ranibizumab Susvimo Vabysmo eye Byooviz aflibercept age-related macular degeneration Avastin Beovu bevacizumab ...
Faricimab-svoa (Vabysmo – Genentech), an inhibitor of both vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2), has been approved by the FDA for intravitreal treatment of neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME). It is the first drug to become available in the US that targets two pathways involved in maintaining vascular homeostasis. Several VEGF inhibitors are available for treatment of nAMD and DME (see Table 2).
Med Lett Drugs Ther. 2022 Mar 21;64(1646):45-6 |  Show IntroductionHide Introduction